Travere Therapeutics (NASDAQ:TVTX) Insider Sells $13,668.45 in Stock

Key Points

• Insider selling: Director/executive Jula Inrig sold 311 shares on May 6 at $43.95 under a pre‑arranged Rule 10b5‑1 plan to cover tax withholding—reducing her position by 0.27% to 113,238 shares—and has executed several larger sales in early May (including 20,000 shares on May 4); director Roy Baynes also sold 9,750 shares recently.
• Business and analyst backdrop: Travere posted a Q1 EPS beat ($0.05 vs. -$0.24 est.) with revenue up 55.6% YoY, and multiple firms raised price targets (e.g., Citigroup $59, TD Cowen $60, HC Wainwright $57), leaving a consensus target of $47.83 while shares trade near $44.70.

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider Jula Inrig sold 311 shares of Travere Therapeutics stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $43.95, for a total value of $13,668.45. Following the completion of the transaction, the insider owned 113,238 shares of the company's stock, valued at $4,976,810.10. The trade was a 0.27% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jula Inrig also recently made the following trade(s):

• On Tuesday, May 5th, Jula Inrig sold 2,174 shares of Travere Therapeutics stock. The shares were sold at an average price of $46.65, for a total value of $101,417.10.
• On Monday, May 4th, Jula Inrig sold 20,000 shares of Travere Therapeutics stock. The shares were sold at an average price of $45.00, for a total value of $900,000.00.
• On Wednesday, April 15th, Jula Inrig sold 1,018 shares of Travere Therapeutics stock. The shares were sold at an average price of $42.61, for a total value of $43,376.98.
• On Tuesday, April 14th, Jula Inrig sold 7,215 shares of Travere Therapeutics stock. The stock was sold at an average price of $41.93, for a total value of $302,524.95.

Travere Therapeutics Stock Down 0.2%

Shares of NASDAQ TVTX traded down $0.10 during midday trading on Wednesday, hitting $44.70. 2,390,035 shares of the company's stock were exchanged, compared to its average volume of 2,890,153. The company has a debt-to-equity ratio of 3.16, a current ratio of 3.13 and a quick ratio of 2.70. Travere Therapeutics, Inc. has a twelve month low of $13.88 and a twelve month high of $48.61. The company has a market cap of $4.16 billion, a PE ratio of -194.33 and a beta of 1.13. The firm's fifty day simple moving average is $32.59 and its 200-day simple moving average is $32.83.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last issued its earnings results on Monday, May 4th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.29. Travere Therapeutics had a negative return on equity of 26.16% and a negative net margin of 4.00%.The business had revenue of $127.20 million for the quarter, compared to analyst estimates of $136.23 million. During the same quarter last year, the company earned ($0.47) EPS. The business's quarterly revenue was up 55.6% on a year-over-year basis. Research analysts predict that Travere Therapeutics, Inc. will post -0.16 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Arizona State Retirement System increased its holdings in shares of Travere Therapeutics by 1.5% in the third quarter. Arizona State Retirement System now owns 24,964 shares of the company's stock valued at $597,000 after purchasing an additional 375 shares during the period. Smartleaf Asset Management LLC increased its holdings in shares of Travere Therapeutics by 69.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,193 shares of the company's stock valued at $45,000 after purchasing an additional 487 shares during the period. Comerica Bank increased its holdings in shares of Travere Therapeutics by 77.5% in the fourth quarter. Comerica Bank now owns 1,127 shares of the company's stock valued at $43,000 after purchasing an additional 492 shares during the period. ProShare Advisors LLC increased its holdings in shares of Travere Therapeutics by 4.1% in the fourth quarter. ProShare Advisors LLC now owns 19,007 shares of the company's stock valued at $726,000 after purchasing an additional 756 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in Travere Therapeutics by 26.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,348 shares of the company's stock worth $166,000 after acquiring an additional 902 shares during the period.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. HC Wainwright raised their target price on Travere Therapeutics from $47.00 to $57.00 and gave the stock a "buy" rating in a research report on Tuesday. Citigroup raised their target price on Travere Therapeutics from $53.00 to $59.00 and gave the stock a "buy" rating in a research report on Tuesday. Wedbush raised their target price on Travere Therapeutics from $53.00 to $55.00 and gave the stock an "outperform" rating in a research report on Tuesday. Wells Fargo & Company raised their target price on Travere Therapeutics from $40.00 to $50.00 and gave the stock an "overweight" rating in a research report on Wednesday. Finally, Wall Street Zen lowered Travere Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Saturday, February 21st. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Travere Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $47.83.

More Travere Therapeutics News

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: TD Cowen raised its price target from $45 to $60 and kept a "buy" rating, implying meaningful upside vs. current levels — a bullish signal from a major sell‑side shop. TD Cowen price target raise
• Positive Sentiment: Wells Fargo upgraded its target to $50 and assigned an "overweight" rating, another near‑term positive catalyst supporting higher valuation expectations. Wells Fargo price target raise
• Neutral Sentiment: HC Wainwright reiterated a "Buy" and $57 target but trimmed FY2027–FY2030 EPS forecasts slightly (e.g., FY2027 cut from $0.71 to $0.60; FY2030 to $4.59 from $4.61). The firm still models substantial multi‑year growth, so this is more of a modest forecast tweak than a change in conviction. HC Wainwright note
• Neutral Sentiment: Earnings call transcript for Q1 2026 is available — recall Travere reported a year‑over‑year revenue gain and an EPS beat in the quarter, which helped underpin recent analyst upgrades. Review the transcript for management commentary on sparsentan commercialization and margin trajectory. Q1 2026 earnings transcript
• Negative Sentiment: Director Roy Baynes sold 9,750 shares (about $431k at the sale price) under a pre‑arranged Rule 10b5‑1 plan. Insider sales can be perceived negatively by the market despite the trading plan disclosure; monitor for any further insider activity. Insider sale filing

About Travere Therapeutics

Travere Therapeutics, Inc NASDAQ: TVTX is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.